Novartis (NVS) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $297.14B | Exchange | NYSE |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | CH | CEO | Vas Narasimhan |
| IPO Date | 1996-11-07 | CAGR | 3.26% |
| Employees | 75,267 | Website | www.novartis.com |
| Div. Yield | 2.94% | Payout Ratio | 68% |
| Buy Back Yield | 2.35% | Total Yield | 5.29% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $340.33B | P/E | 17.99 | Forward P/E | 15.83 | PEG | -1.37 |
| P/S | 5.34 | P/B | 7.06 | P/CF | 16.24 | P/FCF | 18.34 |
| Sales | $55.63B | Sales 1Y | 0.81% | Sales 3Y | 19.23% | Sales 5Y | 7.91% |
| EPS | $8.69 | EPS 1Y | -3.35% | EPS 3Y | 84.68% | EPS 5Y | 67.85% |
| Sales QoQ | 6.61% | EPS QoQ | 3.64% | Sales QoQ Avg | -0.58% | EPS QoQ Avg | -1.11% |
| Gross Margin | 74.29% | Operating Margin | 29.86% | Profit Margin | 23.09% | ROCE | 18.07% |
| ROA | 10% | ROE | 30% | Altman Z Score | 3.51 | Piotroski Score | 6 |
| Current Ratio | 0.86 | Quick Ratio | 0.67 | Cash Ratio | 0.24 | Op. CF Ratio | 0.19 |
| Debt/Equity | 1.18 | Debt/Assets | 0.4 | Lt Debt/Equity | 0.94 | Lt Debt/Cap. | 0.47 |
| Intrst Cov. | 11.88 | Inventory Turnover | 2.26 | Asset Turnover | 0.45 | Receivables Turnover | 5.54 |
| Enterprise Value | $340.33B | P/E Ratio | 17.99 |
| Forward P/E | 15.83 | PEG Ratio | -1.37 |
| P/S Ratio | 5.34 | P/B Ratio | 7.06 |
| P/CF Ratio | 16.24 | P/FCF Ratio | 18.34 |
| EPS | $8.69 | EPS Growth 1Y | -3.35% |
| EPS Growth 3Y | 84.68% | EPS Growth 5Y | 67.85% |
| Revenue Growth 1Y | 0.81% | Gross Margin | 0.74% |
| Operating Margin | 0.3% | Profit Margin | 0.23% |
| ROE | 0.3% | ROA | 0.1% |
| ROCE | 0.18% | Current Ratio | 0.86 |
| Quick Ratio | 0.67 | Cash Ratio | 0.24 |
| Debt/Equity | 1.18 | Interest Coverage | 11.88 |
| Altman Z Score | 3.51 | Piotroski Score | 6 |
Novartis (NVS) valuation & financials
Novartis (NVS) has a market capitalization of $297.14B and trades at a price-to-earnings ratio of 18.0. It operates in the Healthcare sector (Drug Manufacturers - General).
Novartis's revenue grew +0.8% over the last year.
Novartis's next earnings report is scheduled for October 27, 2026 before market open; analysts estimate EPS of $2.24. Check the earnings calendar to see all companies reporting this week.
Novartis (NVS) — frequently asked questions
When does Novartis (NVS) report earnings next?
Novartis is expected to report earnings on October 27, 2026 before market open. Analysts estimate EPS of $2.24.
What is Novartis's market cap?
Novartis (NVS) has a market capitalization of $297.14B.
What is NVS's P/E ratio?
Novartis trades at a price-to-earnings ratio of 18.0, with trailing twelve-month EPS of $8.69.
How fast is Novartis growing?
Novartis's revenue grew +0.8% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)